在急性不补偿性心力衰竭中,levosimendan与dobutamine对比:随机对照试验的系统综述和元分析
Hilson Amorim Parente1, Matheus Dos Santos Silva de Oliveira2, João Vitor Fazzio de Andrade Cordeiro3
1Intensive Care Unit, Barra D'Or Hospital, Rio de Janeiro, Rio de Janeiro, Brazil dr.hilsonparente@gmail.com.
Heart (British Cardiac Society)
|November 12, 2025
概括
与dobutamine相比,levosimendan显著降低了急性不补偿性心力衰竭 (ADHF) 患者的30天死亡率和住院时间. 需要进一步的研究来证实这些发现对ADHF治疗.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 急性不补偿性心力衰竭 (ADHF) 减少喷射分数往往需要内支持.
- 多布他胺是一种常见的治疗方法,但其安全性和有效性仍在争论中.
- 莱沃西门丹是一种潜在的替代品,具有独特的药理特性.
研究的目的:
- 为了在ADHF患者中比较levosimendan与dobutamine的短期临床结果.
- 评估对所有原因死亡率,住院和功能的影响.
主要方法:
- 随机对照试验 (RCT) 的系统审查和元分析.
- 搜索了PubMed,Embase和Cochrane图书馆的相关研究.
- 包括8项与1973名成年ADHF患者的RCT.
主要成果:
- 与多布他胺相比,levosimendan显著降低了30天死亡率 (OR0.53,95% CI 0.31至0.91).
- 随着levosimendan,住院时间平均减少了2.4天,尽管异质性很高.
- 有限的数据表明,使用levosimendan.com对功能有潜在的益处.
结论:
- 与dobutamine相比,levosimendan显示ADHF患者的短期死亡率和住院时间减少.
- 对于死亡率的证据确定性是中等的,对于住院时间是非常低的.
- 建议进行更大的临床试验来验证这些发现.
更多相关视频
相关概念视频
01:30Heart Failure V: Medical Management
207
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
207
01:26Heart Failure Drugs: Inotropic Agents
1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
01:22Heart Failure Drugs: β-Blockers
747
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
747
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:30Heart Failure IV: Classification and Diagnostic Evaluation
305
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
305
01:29Heart Failure II: Pathophysiology
695
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
695